abstract |
The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and andro-gen-independent prostate tumors. It also provides antibodies to PSCA. Further, methods of detection/diagnosis and treatment, as well as a transgenic animal are provided. |